|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
19 February 2015 |
|
Main ID: |
NCT00426296 |
|
Date of registration:
|
23/01/2007 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
SHARE: Simple HAART With Abacavir, Reyataz, and Epivir
|
|
Scientific title:
|
An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of Abacavir 600 mg/Lamivudine 300 mg Once-Daily in Combination With Atazanavir 300 mg + Ritonavir 100 mg Once-Daily in Antiretroviral-Naïve HIV-1 Infected Subjects With Continuing Evaluation of Abacavir/Lamivudine Plus Atazanavir 400 mg for Maintenance Over an Additional 48 Weeks |
|
Date of first enrolment:
|
August 2006 |
|
Target sample size:
|
|
|
Recruitment status: |
Recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT00426296 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
|
|
Phase:
|
Phase 4
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Richard A Elion, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Whitman-Walker Clinic |
|
|
Name:
|
Richard Elion, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
drrelion@aol.com |
|
Affiliation:
|
|
|
|
Name:
|
Richard A. Elion, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
drrelion@aol.com |
|
Affiliation:
|
|
|
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Currently taking abacavir/lamivudine (Epzicom) in combination with atazanavir
(Reyataz) boosted with ritonavir (Norvir) as first antiretroviral regimen
- Viral load <50 copies/ml
Exclusion Criteria:
- Viral load >50 copies/ml
- Having taken more than one antiretroviral regimen
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
HIV Infections
|
|
Lipodystrophy
|
|
Intervention(s)
|
|
Drug: ritonavir (Norvir)
|
|
Drug: atazanavir (Reyataz)
|
|
Secondary ID(s)
|
|
COL102060
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|